NN

Narayana Nethralaya at BioTechX Europe 2026

Oct 6–8, 2026 Basel, Switzerland ~3k attendees Website

Narayana Nethralaya takes part in 2 sessions at BioTechX Europe 2026 in Basel. Its sessions cover bringing AI into clinical trials, alongside Novartis, SAS and Roche, and gene therapy for a muscle-wasting disease. The gene therapy work reviews progress and hurdles in using AAV vectors, modified harmless viruses, to treat Duchenne muscular dystrophy.

OrganizationBioTechX Europe 2026 Attendance
NN
Narayana Nethralaya
Bengaluru, India
Academic & healthcare
Eye hospital group with a research arm.
Panel
Tue Oct 6
17:25
Navigating AI Adoption in Clinical Trials
AI in Clinical Trials · with Novartis, SAS, Roche
Talk
Wed Oct 7
16:30
AAV Vector-mediated DMD Treatment: Advancements and Challenges
Bioinformatics + InSilico R&D

Explore the full BioTechX Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Basel. Leave your work email and we’ll be in touch.

Privacy

Download the full BioTechX Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Narayana Nethralaya

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Terrapinn or BioTechX. Submit a correction